359,550 Shares in Agios Pharmaceuticals, Inc. $AGIO Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 359,550 shares of the biopharmaceutical company’s stock, valued at approximately $13,343,000.

Other large investors also recently added to or reduced their stakes in the company. Creative Planning boosted its stake in shares of Agios Pharmaceuticals by 2.2% in the 3rd quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 280 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Agios Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock worth $4,393,000 after buying an additional 512 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 588 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in Agios Pharmaceuticals by 3.4% in the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 662 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in Agios Pharmaceuticals by 1.4% in the second quarter. California State Teachers Retirement System now owns 47,659 shares of the biopharmaceutical company’s stock valued at $1,585,000 after buying an additional 671 shares during the period.

Analyst Ratings Changes

A number of equities analysts have issued reports on AGIO shares. Bank of America raised their price objective on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a research note on Monday. Citigroup increased their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Truist Financial reduced their price target on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.25.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider owned 54,645 shares of the company’s stock, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company’s stock.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock opened at $33.90 on Wednesday. The company has a market capitalization of $2.02 billion, a P/E ratio of -4.84 and a beta of 0.58. The business has a 50-day moving average of $35.89 and a two-hundred day moving average of $31.51. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. On average, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.8 EPS for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.